Congress highlights
ASCO GU 2023: focus on mCRPC
PARP inhibitors: where do we go from here?
By Dawn O’Shea
With PARP inhibitors (PARPIs) now firmly established in the treatment of metastatic castration-resistant prostate cancer (mCRPC), questions remain to be answered as to how PARPIs should fit into the treatment paradigm and which patients should receive them.
Don’t miss the latest developments in mCRPC from ASCO GU 2023 with exclusive coverage from Medthority
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Recommendations on sequencing mCRPC therapies
By Dawn O’Shea
As the therapeutic armamentarium for metastatic castration-resistant prostate cancer (mCRPC) continues to grow, the burning question is, what is the optimal sequence for first-, second- and third-line settings to deliver the maximum benefit to patients?
That was the dilemma addressed by Dr Silke Gillessen, from the Oncology Institute of Southern Switzerland, at this year’s ASCO Genitourinary Symposium3.
“The most important factor in the choice of first-line treatment for mCRPC is what treatment the patient received in the hormone sensitive setting,” she said.
Don’t miss the latest developments in mCRPC from ASCO GU 2023 with exclusive coverage from Medthority
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
New therapeutic targets and concepts for mCRPC
By Dawn O’Shea
Intratumour myeloid cells, T cell exhaustion and metabolic dependencies are just some of a myriad of the new therapeutic targets that are being explored for the treatment of prostate cancer, presentations at the 2023 ASCO Genitourinary Symposium showed. The data suggest a wave of new therapies may be on the horizon.
With such an array of novel therapies under investigation, Johann Sebastian de Bono from University College London Cancer Institute, gave an overview of new targets and new concepts for the treatment of prostate cancer5.
“Selective tumour cell death remains the ‘Holy Grail’ and this is a rapidly burgeoning research space,” he said.
Targets that are currently being explored include androgen receptor (AR) gene splicing, apoptosis inhibition, novel synthetic lethal strategies, metabolic dependencies, epigenetic remodelling, and novel immunotherapy strategies.
Don’t miss the latest developments in mCRPC from ASCO GU 2023 with exclusive coverage from Medthority
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
of interest
are looking at
saved
next event
Developed by EPG Health for Medthority. This content has been developed independently of the sponsors Pfizer, who have reviewed the content only for scientific accuracy. EPG Health received funding from the sponsor in order to help provide healthcare professionals with access to the highest quality medical and scientific information, education and associated relevant content.